Imidacloprid-Permethrin-Pyriproxyfen

Verify with FDA CVM →

44 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
44
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Imidacloprid-Permethrin-Pyriproxyfen

Administration Routes

TopicalOther

Species Affected

Dog 43
Human 1

Most Affected Breeds

Dog (unknown) 5
Spitz - German Pomeranian 3
Siberian Husky 3
Poodle - Miniature 2
Shepherd Dog - Australian 2
Chihuahua 2
Crossbred Canine/dog 2
Bulldog 2
Spaniel - Cocker English 2
Unknown 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 31
Scratching 3
Lethargy (see also Central nervous system depression in Neurological) 3
Hyperactivity 2
Pruritus 2
Skin lesion NOS 2
Erythema (for urticaria see Immune SOC) 2
Underfilling, Package 2
Other abnormal test result NOS 2
Eye disorder NOS (for Photophobia see neurological) 2
Application site burning sensation 1
Burning sensation (skin) 1

Outcome Breakdown

Outcome Unknown
39 (88.6%)
Recovered/Normal
4 (9.1%)
Ongoing
1 (2.3%)

Data Summary

Metric Value
Total adverse event reports 44
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imidacloprid-Permethrin-Pyriproxyfen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 44 adverse event reports referencing Imidacloprid-Permethrin-Pyriproxyfen, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imidacloprid-Permethrin-Pyriproxyfen. Reported administration routes include Topical, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imidacloprid-Permethrin-Pyriproxyfen reports are Dog (43 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Dog (unknown) (5), Spitz - German Pomeranian (3), Siberian Husky (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imidacloprid-Permethrin-Pyriproxyfen are Lack of efficacy (ectoparasite) - flea (31), Scratching (3), Lethargy (see also Central nervous system depression in Neurological) (3), Hyperactivity (2). Of the 44 reports with a coded outcome, Outcome Unknown is the leading category at 88.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid-Permethrin-Pyriproxyfen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial